Common Contracts
2 similar Underwriting Agreement contracts by Auris Medical Holding AG, Sorrento Therapeutics, Inc.
8,333,334 Shares Series A Warrants to Purchase 8,333,334 Shares Series B Warrants to Purchase 8,333,334 Shares Series C Warrants to Purchase 8,333,334 Shares Sorrento Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 28th, 2019 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • New York
Introductory. Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 8,333,334 shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), (ii) warrants, substantially in the form of Annex A hereto (the “Series A Warrants”), to purchase an aggregate of 8,333,334 shares of Common Stock with an exercise price equal to $3.75 per share (the “Firm Series A Warrants”), (iii) warrants, substantially in the form of Annex B hereto (the “Series B Warrants”), to purchase an aggregate of 8,333,334 shares of Common Stock with an exercise price equal to $3.00 per share (the “Firm Series B Warrants”), and (iv) warrants, substantially in the form of Annex C hereto (the “Series C Warrants”), to purchase an aggregate of 8,333,334 shares of Common Stock with an exercise price equal to $3.75 per share (the “Firm Series C Warrants”, and toge
10,000,000 Shares and Warrants to Purchase 7,000,000 Shares Auris Medical Holding AG UNDERWRITING AGREEMENTUnderwriting Agreement • February 21st, 2017 • Auris Medical Holding AG • Pharmaceutical preparations • New York
